Study of sofetabart mipitecan for ovarian cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer called high-grade serous or endometrioid.
- You have a tumor sample (tissue block or slides) available for testing.
- Your cancer has grown or spread after your most recent treatment.
- You are able to take care of yourself and do light activities (ECOG score 0–1).
- If your cancer came back within 6 months of platinum chemo, you have had 1–3 prior chemo treatments (or up to 4 if one was mirvetuximab soravtansine) and have tried bevacizumab and a PARP inhibitor if you have a BRCA mutation.
- If your cancer came back more than 6 months after platinum chemo, you have had 1–2 prior chemo treatments and have not had a PARP inhibitor (if in Part C) or have had one and it stopped working (if in Part B).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This trial tests a new drug called IBI354 against standard chemotherapy for people with ovarian, primary peritoneal, or fallopian tube cancer that stopped responding to platinum-based treatments. It aims to see if the new drug works better and has fewer side effects.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.